Optimising Accuracy and Cost-Effectiveness of Screening for Pulmonary Arterial Hypertension in Scleroderma [ 2014 - 2017 ]

Also known as: Optimising Screening for Scleroderma Heart-Lung Disease

Research Grant

[Cite as]

Researchers: Dr Mandana Nikpour (Principal investigator)

Brief description Scleroderma is one of the most devastating diseases of the immune system. With features that affect every organ in the body, scleroderma shortens the average patient’s life by over three decades. Pulmonary arterial hypertension (PAH), a condition of increased resistance in the blood vessels of the lungs, is the major cause of death in this disease. The purpose of this project is to develop a new 'screening' model for the early detection of PAH in scleroderma, thereby enabling earlier initiation of life-saving treatment.

Funding Amount $AUD 375,403.97

Funding Scheme Early Career Fellowships

Notes Australian Clinical Research ECF

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]